Synopsis
Recognise cumulative anticholinergic and sedative toxicity, distinguish drug effects from acute disease, and reduce exposure safely while protecting the clinical indications, withdrawal risks and functional priorities of older adults.
- Anticholinergic burden is cumulative exposure to medicines with antimuscarinic effects; sedative burden similarly reflects combined CNS-depressant effects.
- Suspect harm when delirium, memory decline, dry mouth, blurred vision, constipation, retention, falls or daytime sleepiness follows a drug change.
- First-line assessment reconciles every prescribed and purchased product, alcohol, dose, timing, indication, renal function and recent addition or escalation.
- Burden scores can prompt review but differ by scale and do not prove causality or replace examination and acute-illness assessment.
- High-yield classes include bladder antimuscarinics, tricyclic antidepressants, sedating antihistamines, antipsychotics, opioids, benzodiazepines, Z-drugs and gabapentinoids.
- Opioid plus benzodiazepine exposure can cause fatal respiratory depression; prescribe together only when alternatives are inadequate and monitor closely.
- First reduce the medicine with weakest indication or greatest harm, while treating pain, sleep, mood, bladder or behavioural needs through safer alternatives.
- Do not abruptly stop long-term benzodiazepines, Z-drugs, opioids, gabapentinoids, antidepressants or antipsychotics; use an individual supported taper.
- Protect hydration, bowel and bladder function, vision, hearing, mobility and night-time toileting while medicine changes take effect.
- Review actual alertness, cognition, falls and function after change, and communicate discontinued drugs so outdated lists do not restart them.
Key red flags
Respiratory rate reduction, hypoxia, marked sedation or difficult arousal during opioid or benzodiazepine exposure requires emergency assessment.
Hot dry skin, dilated pupils, tachycardia, retention, ileus and agitated delirium suggests severe antimuscarinic toxicity.
New focal deficit, meningism, hypoglycaemia, sepsis or head injury must not be mislabelled as medication-related confusion.
Fall with head strike or inability to weight bear during sedative treatment requires parallel trauma assessment.
Abrupt cessation after long exposure can cause seizure, delirium, autonomic instability or severe psychological withdrawal.
Renal decline, dehydration or addition of another CNS depressant can convert a stable dose into acute accumulation.
Reduced consciousness, slow breathing and pinpoint pupils requires emergency support and antidote consideration.
Acute fluctuation accompanies infection, retention, pain and several risky medicines rather than one isolated cause.
Investigation priorities
Identify additive effects and recent change.
Management branches
Cognitive, bowel, bladder, sleep or mobility change may be medicine-related.
- Reconcile all exposures and establish symptom timing, cognitive baseline, organ function and the indication for each contributor.
- Exclude and treat acute illness, retention, loading, hypoxia, pain and neurological danger while using burden tools only as prompts.
- Prioritise the weakest-benefit, highest-harm exposure and agree a supported reduction or substitution with outcome measures.